BioSpace News Archive

Genetown

Conquering Biopharma’s Post-Pandemic Recruitment Challenge

With multiple job openings across the industry, biotech and biopharma employers have to come up with different strategies to retain top talent.

September 15, 2021
·
5 min read
·
Alex Keown
Life Sciences Companies That are “C"ing Green This Week

Life sciences companies reeled in millions of dollars in Series C financing rounds this week. Here is a look at a few of those companies and what their fresh funds will be used for.

September 15, 2021
·
2 min read
·
Ellen Bombela
Business

Money on the Move: September 8 – 14

Ramping up after the Labor Day holiday, funds are flowing fast and free into these life science companies.

September 15, 2021
·
5 min read
·
Kate Goodwin
Drug Development

Sanofi Shutters Principia’s San Francisco Labs Days After BTK Failure

Sanofi is shuttering Principia’s laboratories in San Francisco after its Phase III PEGASUS trial of rilzabrutinib for pemphigus failed to meet primary or key secondary endpoints.

September 15, 2021
·
3 min read
·
Mark Terry
Drug Development

Study: Survivors of Severe COVID-19 at Risk for Autoimmune Disease

According to the study, people who get sick enough to be hospitalized due to the virus might eventually suffer from a full-blown autoimmune disease later on.

September 15, 2021
·
2 min read
·
Vanessa Doctor, RN
ESMO Preview: Highlights to Watch for This Year

The European Society for Medical Oncology Congress 2021 runs from September 16–21, 2021. Here’s a preview of some of the presentations at the meeting.

September 15, 2021
·
3 min read
·
Mark Terry
Business

Roche and Temedica Pilot Digital Companion for MS Patients

The mobile app, dubbed Brisa, has been designed to help patients record their disease progression regardless of condition and treatment plans.

September 15, 2021
·
2 min read
·
Alex Keown
Global Roundup: TreeFrog Scores $75 Million, Establishes US Toehold

Biopharma and life sciences companies and organizations from across the globe provide updates on their businesses and pipelines.

September 15, 2021
·
7 min read
·
Alex Keown
Drug Development

Theravance Lays Off 270 in Aftermath of Cardiac Asset Failure

The company announced a Phase III cardiac drug failed to meet its primary endpoint and a significant shift in its R&D efforts that have resulted in the termination of 75% of its staff.

September 15, 2021
·
4 min read
·
Alex Keown
Drug Development

Brukinsa Accelerated Approval in Lymphoma Makes Two in a Row for BeiGene

Brukinsa was approved for MSL patients who have received at least one anti-CD20-based regimen.

September 15, 2021
·
2 min read
·
Alex Keown